To include your compound in the COVID-19 Resource Center, submit it here.

Anaphore, arGEN-X B.V. deal

Anaphore changed its name to RuiYi Inc. and announced a deal for exclusive, worldwide rights to a preclinical anti-IL-6 mAb from arGEN-X. RuiYi

Read the full 238 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE